Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacological Characterization of KR-31125, a Novel Nonpeptide AT1 Receptor Antagonist

안지오텐신 수용체 길항제 KR-31125의 특성에 관한 연구

  • Lee, Sung-Hou (Department of Biomedical Technology, College of Engineering, Sangmyung University)
  • 이승호 (상명대학교 공과대학 의생명공학과)
  • Received : 2010.02.25
  • Accepted : 2010.05.13
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

KR-31125 (2-butyl-5-dimethoxymethyl-6-phenyl-7-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3H-imidazo[4,5-b]pyridine) is a potent inhibitor of angiotensin II type 1 ($AT_1$) receptors in human recombinant $AT_1$ receptors and rabbit aorta. These in vitro studies revealed that KR-31125 inhibited specific [$^{125}I$] [$Sar^1$, $Ile^8$]-angiotensin II binding to human recombinant $AT_1$ receptors in a concentration dependent manner with an $IC_{50}$ value of $19.72{\pm}2.65$ nM. However, no interaction with $AT_2$ receptors was detected as displayed by the competition binding of [$^{125}I$] CGP 42112A to human recombinant $AT_2$ receptor. The binding action was also confirmed as a competitive mode that was identical to the previously studied compound, losartan. In addition, KR-31125 caused a nonparallel shift to the right in the concentration response curves to angiotensin II with a 30-80% decrease in the maximum contractile responses ($pK_B$: 7.63). Compared to the previous studies with losartan that showed a parallel right shift in the maximum contractile responses to AII ($pA_2$: 7.59), KR-31125 presented a different mode of action with a similar potency to losartan. These results demonstrate that KR-31125 is a highly potent and $AT_1$ selective angiotensin II receptor antagonist that can be applied to the fields of new diagnostic and research tools with upcoming in vivo study results.

KR-31125는 피리딜 이미다졸 시리즈 화합물로서 비펩타이드 안지오텐신 수용체 길항제로 새롭게 개발되었다. 동위원소 리간드를 사용한 재조합 수용체 결합실험과 기능성 토끼혈관실험 결과 기존 의약인 로자탄과 동등수준의 수용체 길항효과를 나타내었다. 이러한 KR-31125의 특징들은 제 1형 안지오텐신 수용체에 특이적으로 나타났으며($IC_{50}$: $19.72{\pm}2.65\;nM$), 표준물질에 대한 대조실험 결과 제 2형 안지오텐신 수용체에 대한 결합친화력은 발견되지 않았다. 기능성 혈관실험에서 KR-31125가 안지오텐신에 의한 혈관수축 효과를 경쟁적으로 저하시켰지만 표준물질인 로자탄과는 달리 농도가 증가함에 따라 30-80% 정도의 최대 수축효과 감소가 관찰되어 로자탄과는 다른 분자작용 기전을 가진다고 판단된다. 제 1형 안지오텐신 수용체에 선택적으로 작용하는 것으로 나타난 KR-31125는 레닌-안지오텐신-알도스테론 시스템에 대한 연구 및 진단에 폭 넓게 활용될 수 있는 표지자 화합물로 가능성을 넓혀 줄 수 있을 것이라고 판단된다.

Keywords

References

  1. Baker, J. G., R. Middleton, L. Adams, L. T. May, S. J. Briddon, B. Kellam, and S. J. Hill. 2010. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A receptor ligands. Br. J. Pharmacol. epub ahead of print
  2. Cheng, Y. and W. H. Prusoff. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108. https://doi.org/10.1016/0006-2952(73)90196-2
  3. Cody, R. J. 1986. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure. J. Cardiovasc. Pharmacol. 8 Suppl 1, S58-65.
  4. Coulter, D. M. and I. R. Edwards. 1987. Cough associated with captopril and enalapril. Br. Med. J. (Clin Res Ed). 294, 1521-1523. https://doi.org/10.1136/bmj.294.6586.1521
  5. Dahlof, B., S. E. Keller, L. Makris, A. I. Goldberg, C. S. Sweet, and N. Y. Lim. 1995. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am. J. Hypertens. 8, 578-583. https://doi.org/10.1016/0895-7061(95)00081-Y
  6. Dickstein, K., S. Gottlieb, E. Fleck, J. Kostis, B. Levine, M. DeKock, and T. LeJemtel. 1994. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J. Hypertens. Suppl. 12, S31-35.
  7. Hilditch, A., A. A. Hunt, A. Travers, J. Polley, G. M. Drew, D. Middlemiss, D. B. Judd, B. C. Ross, and M. J. Robertson. 1995. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist. J. Pharmacol. Exp. Ther. 272, 750-757.
  8. Mallion, J. M. and A. I. Goldberg. 1996. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press Suppl. 2, 82-86.
  9. Mathews, W. B., S. E. Yoo, S. H. Lee, U. Scheffel, P. A. Rauseo, T. G. Zober, G. Gocco, K. Sandberg, H. T. Ravert, R. F. Dannals, and Z. Szabo. 2004. A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl. Med. Biol. 31, 571-574. https://doi.org/10.1016/j.nucmedbio.2003.10.014
  10. May, L. T., S. J. Briddon, and S. J. Hill. 2010. Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions. Mol. Pharmacol. 77, 678-686. https://doi.org/10.1124/mol.109.063065
  11. Panek, R. L., G. H. Lu, R. W. Overhiser, T. C. Major, J. C. Hodges, and D. G. Taylor. 1995. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharmacol. Exp. Ther. 273, 753-761.
  12. Roberts, J. R. and R. C. Wuerz. 1991. Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann. Emerg. Med. 20, 555-558. https://doi.org/10.1016/S0196-0644(05)81616-6
  13. Sever, P. S., A. H. Gradman, and M. Azizi. 2009. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 10, 65-76. https://doi.org/10.1177/1470320309104662
  14. Timmermans, P. B. and R. D. Smith. 1994. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 15 Suppl D, 79-87. https://doi.org/10.1093/eurheartj/15.suppl_D.79
  15. Vallotton, M. B. 1987. The renin-angiotensin system. Trends Pharmacol Sci. 8, 69-74. https://doi.org/10.1016/0165-6147(87)90013-7
  16. Wienen, W., N. Hauel, J. C. Van Meel, B. Narr, U. Ries, and M. Entzeroth. 1993. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110, 245-252. https://doi.org/10.1111/j.1476-5381.1993.tb13800.x
  17. Wienen, W., A. B. Mauz, J. C. Van Meel, and M. Entzeroth. 1992. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol. Pharmacol. 41, 1081-1088.
  18. Williams, G. H. 1988. Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319, 1517-1525. https://doi.org/10.1056/NEJM198812083192305
  19. Wong, P. C., S. D. Hart, J. V. Duncia, and P. B. Timmermans. 1991. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur. J. Pharmacol. 202, 323-330. https://doi.org/10.1016/0014-2999(91)90274-T
  20. Wong, P. C., W. A. Price, A. T. Chiu, J. V. Duncia, D. J. Carini, R. R. Wexler, A. L. Johnson, and P. B. Timmermans. 1990. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 252, 726-732.
  21. Wong, P. C., W. A. Price, Jr., A. T. Chiu, J. V. Duncia, D. J. Carini, R. R. Wexler, A. L. Johnson, and P. B. Timmermans. 1991. In vivo pharmacology of DuP 753. Am. J. Hypertens. 4, 288S-298S. https://doi.org/10.1093/ajh/4.3.288
  22. Xia, J., E. Seckin, Y. Xiang, M. Vranesic, W. B. Mathews, K. Hong, D. A. Bluemke, L. O. Lerman, and Z. Szabo. 2008. Positron-emission tomography imaging of the angiotensin II subtype 1 receptor in swine renal artery stenosis. Hypertension 51, 466-473. https://doi.org/10.1161/HYPERTENSIONAHA.107.102715
  23. Zober, T. G., M. E. Fabucci, W. Zheng, P. R. Brown, E. Seckin, W. B. Mathews, K. Sandberg, and Z. Szabo. 2008. Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney. Eur. J. Nucl. Med. Mol. Imaging. 35, 1109-1116. https://doi.org/10.1007/s00259-007-0667-z
  24. Zober, T. G., W. B. Mathews, E. Seckin, S. E. Yoo, J. Hilton, J. Xia, K. Sandberg, H. T. Ravert, R. F. Dannals, and Z. Szabo. 2006. PET Imaging of the AT1 receptor with [11C]KR31173. Nucl. Med. Biol. 33, 5-13. https://doi.org/10.1016/j.nucmedbio.2005.08.005